England’s New Innovative Medicines Fund ‘Must Be Future Proof’
A public engagement exercise on the new plan in due in Q1 2021
When establishing the new fund, lessons should be learned from the Cancer Dugs Fund so other disease areas are not neglected, say experts.
You may also be interested in...
Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.
More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform.
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.